Adipotide
Prohibitin-targeting peptide 1 (Prohibitin-TP01)
Adipotide is a revolutionary experimental vascular-targeting peptidomimetic designed to induce selective apoptosis in blood vessels supplying white adipose tissue. Also known as Prohibitin-TP01, FTPP (Fat-Targeted Proapoptotic Peptide), or TP-1, it represents a completely novel approach to weight management through direct fat cell elimination rather than appetite suppression. While clinical development was discontinued in 2019 due to nephrotoxicity concerns, preclinical studies demonstrated remarkable efficacy with up to 30% weight reduction in rodent models and 11% weight loss in primate studies over just 28 days.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
CRITICAL WARNING: Adipotide clinical development was permanently discontinued due to unacceptable nephrotoxicity. All human trials were terminated early. This information is for educational purposes only. Adipotide is NOT approved for any human use and carries severe kidney damage risks. Consult healthcare providers for approved weight management alternatives.